Kyntra Bio
KYNB
198 hedge funds and large institutions have $2.47B invested in Kyntra Bio in 2021 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 77 reducing their positions, and 31 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.03% less ownership
Funds ownership: 3.16% → 3.13% (-0.03%)
4% less funds holding
Funds holding: 207 → 198 (-9)
7% less capital invested
Capital invested by funds: $2.67B → $2.47B (-$199M)
21% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 77
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
65% less call options, than puts
Call options by funds: $12.2M | Put options by funds: $34.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$108M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$28M |
| 3 |
Bank of New York Mellon
New York
|
+$23.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.71M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$9.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$73.7M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$21.9M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$20.1M |
| 4 |
AG
Artal Group
Luxembourg
|
-$14.8M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$12.6M |
KYNB Hedge Fund Activity: Q1 2021 in Review
198 of the 5,710 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2021, worth a combined $2.47B — down 7.5% from $2.67B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of KYNB and 23 opened new positions — a net loss of 8 holders — while 77 trimmed existing stakes and 61 added.
The largest buyer was Primecap Management, adding an estimated $108M. The largest seller was T. Rowe Price Associates, cutting an estimated $73.7M.
- 198 institutional investors held Kyntra Bio (KYNB) as of Q1 2021, down from 207 in Q4 2020.
- Funds reported $2.47B of Kyntra Bio stock for Q1 2021, down 7.5% quarter-over-quarter.
- 23 funds opened new Kyntra Bio positions in Q1 2021 and 31 closed out, a net change of -8 holders.
- The largest Kyntra Bio buyer in Q1 2021 was Primecap Management, an estimated $108M added.
- The largest Kyntra Bio seller in Q1 2021 was T. Rowe Price Associates, an estimated $73.7M sold.
Based on aggregated 13F filings for Q1 2021.